UNSPSC 51101679: Pretamazium iodide

This classification denotes an antihelminthic agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7Z32Z641H2. European Medicines Agency schedules Pretamazium iodide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10031MIG. Pretamazium iodide generally arises in the molecular formula C29H29N2S.I. The term PRETAMAZIUM IODIDE is an International Non-Proprietary Name or INN. Most nations schedule pretamazium iodide under HS 29341000 and SITC 51579.

As of Q4 2014, PRETAMAZIUM IODIDE remains the US FDA Preferred Term for this commodity. Pretamazium iodide bears US NLM identifiers UMLS ID C2347671 and NCI Concept Code C74150. SMILES: I.s1c([n](c(c2ccc(cc2)c2ccccc2)c1)CC)/C=C/c1ccc(N2CCCC2)cc1.

UNSPSC 51101679 Pretamazium iodide is a Commodity code representing specialized pharmaceutical products procured through state and local health agencies. Recent state and local opportunities tagged under this code show limited direct alignment with pretamazium iodide itself; instead, solicitations and awards reflect procurement of other pharmaceutical products and medical supplies — including antibiotic tablets, naloxone, and drug deactivation systems — through piggyback contracts, cooperative purchasing consortiums, and competitive bidding processes. State and local health departments and county community health offices are the primary issuing bodies, leveraging established pharmaceutical supply frameworks and emergency preparedness funding to secure products at volume pricing.

The most recent activity centers on Illinois and Florida. The Illinois Department of Public Health awarded a $2.999 million piggyback contract through the MMCAP Infuse consortium to Chartwell Rx LLC on August 28, 2026, for supply of Doxycycline Hyclate 100mg and Ciprofloxacin Hydrochloride 500mg tablets over a 12-month initial term with renewal options through year 3. Seminole County, Florida released an IFB on June 30, 2026, seeking 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually through quarterly deliveries, with electronic bidding and a July 26 response deadline; the procurement included potential FEMA funding and standard compliance requirements for drug-free workplace certification and E-Verify. The code shows minimal recent activity, and the pharmaceutical products actually solicited diverge substantially from the code's nominal scope, suggesting either miscoding in the underlying data or infrequent use of this code for state and local procurement activity.